Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(14%)
Results Posted
75%(3 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
3
43%
Ph phase_1
4
57%

Phase Distribution

4

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Not yet recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (57.1%)
Phase 23 (42.9%)

Trials by Status

not_yet_recruiting114%
completed457%
recruiting114%
terminated114%

Recent Activity

1 active trials
Showing 5 of 7
not_yet_recruitingphase_1

Evaluating the Pharmacokinetics and Safety of Miricorilant

NCT07553663
recruitingphase_1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

NCT06947304
completedphase_1

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

NCT05553470
completedphase_2

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

NCT03818256
completedphase_1

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

NCT05712265
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07553663Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Not Yet Recruiting
NCT06947304Phase 1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Recruiting
NCT05553470Phase 1

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Completed
NCT03818256Phase 2

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

Completed
NCT05712265Phase 1

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Completed
NCT04466215Phase 2

Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo

Completed
NCT03823703Phase 2

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7